You are here

  • Home
  • Archive
  • Volume 34, Issue Suppl 3
  • EV032/#1256  Triple blinded prospective study assessing the impact of genomics & artificial intelligence Watson for oncology (WFO) on MDT’s decision of adjuvant systemic therapy for hormone receptor positive early breast carcinoma

Article info

Article menu
Download PDFPDF
E-Poster Viewing Abstracts
AS02. Breast cancer
EV032/#1256  Triple blinded prospective study assessing the impact of genomics & artificial intelligence Watson for oncology (WFO) on MDT’s decision of adjuvant systemic therapy for hormone receptor positive early breast carcinoma

Authors

Citation

Rohit Kumar C, Prasanna Somashekhar S, Yethadka R, et al
EV032/#1256  Triple blinded prospective study assessing the impact of genomics & artificial intelligence Watson for oncology (WFO) on MDT’s decision of adjuvant systemic therapy for hormone receptor positive early breast carcinoma
International Journal of Gynecologic Cancer 2024;34:A99.

Publication history

  • First published October 18, 2024.
Online issue publication 
October 18, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.